$VICR

Davies Philip D sold $94K of VICR

Davies Philip D (VP Global Sales & Marketing) sold 300 shares of VICOR CORP (VICR) at $314.11 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Philip D
Published Jun 2, 2026, 2:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VICR
Neutral
medium confidence
Mentioned
$VICR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VICRNeutralLow
01

Why it matters

Because the sale is pre-planned, it generally does not imply new negative information about Vicor’s prospects; it mainly updates the insider-trading record.

02

Market read

Insider selling disclosure for VICR; likely low incremental trading impact absent other catalysts.

03

What to watch

The article provides only one small sale; without context on prior insider activity, total shares sold/bought, and timing versus price moves, the signal is weak.

Relevance 6/10Novelty 2/10Timing: Filed today; sale executed 2026-06-01.

Background

This is an SEC Form 4 insider transaction disclosure (open-market sale) by an officer/director of Vicor, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$VICRNeutralMedium confidence
Context

VICR insider (VP Global Sales & Marketing) sold 300 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited, likely short-lived impact; any move would be more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is an SEC Form 4 for a small, pre-planned sale; no earnings, guidance, or deal information is provided.

Market effects

Minimal—no sector-wide catalyst or peer read-across is introduced.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with periods of perceived valuation risk; traders may still fade strength if selling pressure is notable versus typical patterns.

Key entities

  • VICOR CORP

    Subject of the SEC Form 4 insider sale disclosure.

  • Davies Philip D

    VP Global Sales & Marketing; sold 300 shares under a 10b5-1 plan.

Related articles

$VICRMedAI 8/10

Vicor (VICR) Q2 2026 Earnings Call Transcript

Vicor’s Q2 2026 earnings call reported product and royalty revenue of $143.4M, up 26.9% sequentially and 1.6% year over year. Advanced products revenue rose to $94.2M. Net income was $49.8M, GAAP diluted EPS $1.40, and cash was $453.6M. The company guided for nearly 10% Q3 revenue growth and over $600M 2026 revenue, citing capacity increases and licensing assumptions.

$VICRMed

Vicor Corp (VICR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

Vicor Corp said a new license agreement will bring $5 million quarterly payments in year one and $10 million in year two, with $15 million contributing to Q2 revenue and additional revenue recognition expected in Q3 and subsequent quarters. Management also discussed fab capacity expansion to support a $2.5 billion revenue goal and said backlog growth stems mainly from existing customer demand.

$VICRMed

VICOR CORP (VICR): Results of Operations and Financial Condition

VICOR CORP (VICR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d115827dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE FINANCIAL NEWS BRIEF July 21, 2026 For Immediate Release Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2026 Andover, Mass., July 21, 2026 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: